CareDx (CDNA)
(Delayed Data from NSDQ)
$23.98 USD
-0.50 (-2.04%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $24.01 +0.03 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.98 USD
-0.50 (-2.04%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $24.01 +0.03 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
Encompass Health Opens 9th Hospital in SC: More in the Pipeline?
by Zacks Equity Research
This new facility is part of EHC's continued strategy to meet the rising demand for rehabilitative services.
Select Medical Rises 50.2% YTD: Take Profits or Bet on More Gains?
by Zacks Equity Research
SEM's profitability is being impacted by rising costs and expenses.
Teladoc Stock Rises 12% as Jefferies Boosts Price Target on BetterHelp
by Zacks Equity Research
TDOC's stock benefits from improving web traffic in its BetterHelp platform.
Community Health's Arm Northwest Urgent Buys 10 Arizona Facilities
by Zacks Equity Research
CYH expects the acquisition from Carbon Health to be completed in the fourth quarter of 2024.
Pediatrix Medical Up 45.8% in 3 Months: Is it Too Late to Jump In?
by Zacks Equity Research
MD remains one of the best-positioned pediatric service providers with favorable valuation to achieve margin improvement.
Beat the Market Like Zacks: CareDx, Fair Isaac, 3M in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 292.31% and 37.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix (BDSX) delivered earnings and revenue surprises of 6.67% and 5.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
How CareDx (CDNA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 24.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.